Our in vitro biology and screening group offers a wide spectrum of biochemical and cell-based assays to profile small and large molecules entities.
In vitro biology services are offered in stand alone mode or seamlessly integrated with end-to-end drug discovery programs.
Our in vitro biology team has in depth knowledge of different therapeutic areas and target classes. De novo assay development without any literature precedence for novel target classes or therapeutic indications along with assay customization has added significant value to our Integrated Drug Discovery (IDD) projects and driving compound progression and clinical candidate nomination successfully.
Our offerings include screening and profiling services/platforms under different therapeutic areas and target classes.
Platform for screening of NCEs and NBE against major therapeutic target classes:
We focus and cater to a wide range of therapeutic areas like asthma and COPD, metabolic disorders (diabetes, NASH & obesity), inflammation, oncology, immunology, stem cell biology, osteoporosis, angiogenesis, CNS, and pain. We also have experience in epigenetics and Protein-protein Interaction (PPI) target.
At Aurigene we are continuously adding experience of advance and emerging drug classes. As a result, examples include PROTAC, Oligonucleotide, ADC and mRNA. We offer complete set of bioassays for PORTAC discovery.
In vitro assay development:
Good assay development practices at Aurigene include, but not limited to
Aurigene Pharmaceutical Services is
that provides contract research and manufacturing services
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.